•Journal•ISSN: 1664-5553
Liver cancer
Karger Publishers
About: Liver cancer is an academic journal published by Karger Publishers. The journal publishes majorly in the area(s): Hepatocellular carcinoma & Medicine. It has an ISSN identifier of 1664-5553. It is also open access. Over the lifetime, 484 publications have been published receiving 16929 citations. The journal is also known as: hepatic cancer & hepatic neoplasm.
Topics: Hepatocellular carcinoma, Medicine, Internal medicine, Sorafenib, Cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: ALBI grade is a useful and easy classification system for assessment of hepatic function for therapeutic decision making and prognosis based on ALBI grade/ALBI-T score was better than that based on liver damage/modified JIS score and Child-Pugh/JIS score.
Abstract: Aim/Background: The purpose of this study was to evaluate the validity of 3 classifications for assessing liver function, the liver damage and Child-Pugh classifi
2,468 citations
••
TL;DR: The Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma proposed by the Japan Society of Hepatology was updated in June 2014 at a consensus meeting of the Liver Cancer Study Group of Japan.
Abstract: The Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma proposed by the Japan Society of Hepatology was updated in June 2014 at a consensus meeting of the Liver Cancer Study Group of Japan. Three important items have been updated: the surveillance and diagnostic algorithm, the treatment algorithm, and the definition of transarterial chemoembolization (TACE) failure/refractoriness. The most important update to the diagnostic algorithm is the inclusion of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging as a first line surveillance/diagnostic tool. Another significant update concerns removal of the term "lipiodol" from the definition of TACE failure/refractoriness.
506 citations
••
Fudan University1, Second Military Medical University2, Third Military Medical University3, Harbin Medical University4, Sichuan University5, Fourth Military Medical University6, Chinese PLA General Hospital7, Guangdong General Hospital8, Sun Yat-sen University9, Shanghai Jiao Tong University10, China Medical University (PRC)11, Anhui Medical University12, Peking Union Medical College13, Peking University14, Jilin University15, First Affiliated Hospital of Xinjiang Medical University16, Academy of Military Medical Sciences17, Xiamen University18, Zhengzhou University19, Southeast University20, Zhejiang University21, Tsinghua University22, Tianjin Medical University Cancer Institute and Hospital23
TL;DR: A guideline on the surveillance, diagnosis, staging, and treatment of HCC occurring in China is presented, and recommendations regarding patients with HCC in China are made to ensure optimum patient outcomes.
Abstract: Background
Hepatocellular carcinoma (HCC) (about 85–90% of primary liver cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis B infection. HCC is the fourth most common malignancy and the third leading cause of tumor-related deaths in China. It poses a significant threat to the life and health of Chinese people.
406 citations
••
Fudan University1, Second Military Medical University2, Third Military Medical University3, Harbin Medical University4, Sichuan University5, Fourth Military Medical University6, Chinese PLA General Hospital7, Guangdong General Hospital8, Sun Yat-sen University9, Shanghai Jiao Tong University10, China Medical University (PRC)11, Zhengzhou University12, Beijing University of Chinese Medicine13, Anhui Medical University14, Peking Union Medical College15, Peking University16, Jilin University17, Guangxi Medical University18, First Affiliated Hospital of Xinjiang Medical University19, Central South University20, Academy of Military Medical Sciences21, Xiamen University22, Huazhong University of Science and Technology23, Tianjin Medical University Cancer Institute and Hospital24, Guangzhou Medical University25, Southeast University26, Zhejiang University27, Sir Run Run Shaw Hospital28, Tsinghua University29
TL;DR: The new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People’s Republic of China in December 2019 and reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years.
Abstract: Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition) in 2018, additional high-quality evidence has emerged with relevance to the diagnosis, staging, and treatment of liver cancer in and outside China that requires the guidelines to be updated. The new edition (2019 Edition) was written by more than 70 experts in the field of liver cancer in China. They reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years. Key Messages: Most importantly, the new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People’s Republic of China in December 2019.
343 citations
••
TL;DR: Stage-based approach to therapy not only provides acceptable outcomes but also improves the quality of life of HCC patients, whichusses the current standards and trends in the treatment of H CC.
Abstract: Hepatocellular carcinoma (HCC) is one of the most common malignancies, with an increasing incidence. With advances in surgical techniques and instrumentation and the development of molecular-target drugs, a number of potentially curative treatments have become available. Management of HCC patients depends on the stage of their tumor. Liver resection remains the first choice for very early-stage HCC, but it is being challenged by local ablative therapy. For early-stage HCC that meet the Milan criteria, liver transplantation still offers a better outcome; however, local ablative therapy can be a substitute when transplantation is not feasible. Local ablation is also used as a bridging therapy toward liver transplantation. HCC recurrence is the main obstacle to successful treatment, and there is currently no effective means of preventing or treating HCC recurrence. Transarterial therapy is considered suitable for intermediate-stage HCC, while sorafenib is recommended for advanced-stage HCC. This stage-based approach to therapy not only provides acceptable outcomes but also improves the quality of life of HCC patients. Because of the complexity of HCC, therapeutic approaches must be adapted according to the characteristics of each individual patient. This review discusses the current standards and trends in the treatment of HCC.
265 citations